RVPH Stock Price, Reviva Pharmaceuticals Holdings Quote, Chart

Market Summary

USD1.67-0.04

Delayed

-2.34%

RVPH Stock Price

View Fullscreen

RVPH RSI Chart

RVPH Valuation

Market Cap

46.6M

Price/Earnings (Trailing)

-1.17

EV/EBITDA

-0.87

Price/Free Cashflow

-1.45

MarketCap/EBT

-1.16

RVPH Price/Earnings (Trailing)

RVPH Profitability

Return on Equity

3.0K%

Return on Assets

-294.96%

Free Cashflow Yield

-68.85%

RVPH Fundamentals

RVPH Earnings

Earnings (TTM)

-39.8M

Earnings Growth (Yr)

-8%

Earnings Growth (Qtr)

20.9%

Breaking Down RVPH Revenue

Last 7 days

-10.7%

Last 30 days

-47.8%

Last 90 days

-61.2%

Trailing 12 Months

-77.9%

How does RVPH drawdown profile look like?

RVPH Financial Health

Current Ratio

0

RVPH Investor Care

Shares Dilution (1Y)

35.30%

Tracking the Latest Insider Buys and Sells of Reviva Pharmaceuticals Holdings

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 18, 2022	patel purav	bought	14,070	4.69	3,000	-
Sep 30, 2022	narayan prabhu	bought	83,000	1.66	50,000	chief financial officer
Jun 30, 2022	narayan prabhu	bought	60,670	1.2134	50,000	chief financial officer
Jun 01, 2021	vedanta partners, llc	bought	4,987,500	3.75	1,330,000	-
Dec 14, 2020	tenzing llc	acquired	-	-	197,500	-

Which funds bought or sold RVPH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	B. Riley Wealth Advisors, Inc.	new	-	17,096	17,096	-%
May 16, 2024	Colony Group, LLC	added	41.32	23,000	646,000	-%
May 16, 2024	JANE STREET GROUP, LLC	added	3.43	-36,079	113,740	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	sold off	-100	-9,084,600	-	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	-12,740	35,150	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-214,235	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	6.57	-899,439	3,230,380	-%
May 15, 2024	MARSHALL WACE, LLP	reduced	-10.82	-69,564	131,801	-%
May 15, 2024	Polar Asset Management Partners Inc.	unchanged	-	-212,076	585,144	0.01%

Are Funds Buying or Selling RVPH?

Are funds buying RVPH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RVPH

No. of Funds

Unveiling Reviva Pharmaceuticals Holdings's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 16, 2024	bhat laxminarayan	10.2%	2,885,678	SC 13D/A
Feb 14, 2024	tang capital partners lp	9.99%	3,098,615	SC 13G/A
Feb 14, 2024	armistice capital, llc	6.32%	1,764,000	SC 13G
Nov 30, 2023	vedanta partners, llc	9.0%	2,656,918	SC 13D/A
May 05, 2023	bhat laxminarayan	13.5%	2,811,545	SC 13D/A
Feb 14, 2023	tang capital partners lp	9.99%	2,266,229	SC 13G/A
Sep 12, 2022	vedanta partners, llc	12.0%	2,656,918	SC 13D/A
Jan 19, 2021	tenzing llc	27.24%	2,662,250	SC 13D/A
Jan 19, 2021	tenzing llc	22.98%	2,121,750	SC 13D/A
Jan 19, 2021	tenzing llc	6.09%	0	SC 13D/A

Recent SEC filings of Reviva Pharmaceuticals Holdings

View All Filings

Date Filed	Form Type	Document
May 17, 2024	S-8	Employee Benefits Plan
May 15, 2024	8-K	Current Report
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
Apr 15, 2024	8-K	Current Report
Apr 15, 2024	8-K	Current Report
Apr 15, 2024	8-K	Current Report
Apr 15, 2024	10-K	Annual Report
Apr 02, 2024	NT 10-K	NT 10-K
Feb 16, 2024	SC 13D/A	13D - Major Acquisition

Peers (Alternatives to Reviva Pharmaceuticals Holdings)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Reviva Pharmaceuticals Holdings News

Latest updates

Reviva Pharmaceuticals Holdings Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q4	2019Q3
Assets	-43.1%	13,497	23,700	5,387	11,842	12,902	18,924	24,041	20,643	25,268	31,404	33,894	36,535	6,658	8,762	34,694	34,478	34,459	61,022	63,747	66,473	66,270
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	44.00	38.00	240	139	-	150	250
Cash Equivalents	-48.8%	11,974	23,367	4,972	11,152	11,256	18,520	23,192	19,420	23,421	29,688	33,492	35,801	5,644	8,760	37.00	16.00	198	69.00	193*	134	211
Liabilities	-17.5%	14,842	17,982	18,198	13,657	11,288	10,529	6,485	4,583	3,907	2,718	1,625	2,014	2,142	3,297	5,049	4,375	3,840	3,263	6,814	2,314	2,248
Current Liabilities	-15.6%	14,492	17,175	17,324	12,645	10,732	9,962	6,379	4,477	3,623	2,345	974	1,163	1,101	1,333	860	736	501	300	-	100	34.00
Short Term Borrowings	-	332	-	223	223	668	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-123.5%	-1,345	5,719	-12,810	1,621	1,614	8,394	17,556	16,060	21,361	28,686	32,269	34,521	4,516	5,466	5,000	5,000	5,000	5,000	-	5,000	5,000
Retained Earnings	-5.5%	-141,800	-134,354	-124,998	-113,653	-101,945	-95,093	-85,856	-79,500	-74,196	-66,831	-63,147	-60,867	-59,259	-58,310	172	520	1,036	1,192	-54,526	1,324	1,187
Additional Paid-In Capital	0.3%	140,439	140,070	112,186	111,836	103,557	103,486	103,410	95,597	95,557	95,517	95,415	95,387	63,775	63,775	-	-	-	-	18,645	-	-
Shares Outstanding	0%	27,919	27,919	20,650	22,650	20,452	20,447	19,270	18,467	18,467	14,433	13,555	12,875	-	-	-	-	-	-	-	-	-
Float	-100.0%	-	103,700	-	-	-	-	-	11,200	-	-	-	41,400	-	-	-	-	-	-	-	-	59,058

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q4	2020Q3	2020Q3	2020Q2	2020Q2	2020Q1	2020Q1
Cashflow From Operations	-32.1%	-11,725	-8,876	-6,179	-5,317	-7,951	-4,690	-4,001	-4,001	-6,266	-3,902	-2,309	-1,340	-3,116	-3,545	-	-823	-	-379	-35.46	-60.66	-
Share Based Compensation	-5.5%	369	391	350	2,621	52.00	57.00	41.00	40.00	40.00	62.00	28.00	17.00	-	-	-	-	-	-	-	-	-
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-206	-	-210	-	26,773	-	5,702
Cashflow From Financing	-98.8%	332	27,272	-	5,213	687	19.00	7,774	-	70*	98.00	-	31,497	-	38,695	-	27,793	-	27,219	-26,608	230	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	109	-	-	-	26,984	-	6,269

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RVPH Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 5,783,865	$ 5,484,145
General and administrative	2,138,241	1,500,554
Total operating expenses	7,922,106	6,984,699
Loss from operations	(7,922,106)	(6,984,699)
Other income (expense)
Gain on remeasurement of warrant liabilities	456,177	11,126
Interest expense	(3,487)	(7,655)
Interest income	173,098	147,011
Other expense	(129,894)	(14,494)
Total other income, net	495,894	135,988
Loss before provision for income taxes	(7,426,212)	(6,848,711)
Provision for income taxes	7,396	2,978
Net loss	$ (7,433,608)	$ (6,851,689)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.25)	$ (0.31)
Weighted average shares outstanding
Basic and diluted (in shares)	29,887,325	21,833,598

RVPH Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Assets [Abstract]
Cash and cash equivalents	$ 11,973,647	$ 23,367,456
Prepaid clinical trial costs	779,602	78,295
Prepaid expenses and other current assets	743,381	254,637
Total Assets	13,496,630	23,700,388
Liabilities [Abstract]
Short-term debt	332,000	0
Accounts payable	5,720,455	3,849,108
Accrued clinical expenses	6,845,910	11,966,812
Accrued compensation	1,216,237	958,607
Other accrued liabilities	377,367	400,490
Total current liabilities	14,491,969	17,175,017
Warrant liabilities	350,478	806,655
Total Liabilities	14,842,447	17,981,672
Commitments and Contingencies
Stockholders' Equity (Deficit)
Common stock, par value of $0.0001; 115,000,000 shares authorized; 27,918,560 issued and outstanding as of March 31, 2024 and December 31, 2023	2,792	2,792
Preferred Stock, par value of $0.0001; 10,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Additional paid-in capital	140,439,247	140,070,172
Accumulated deficit	(141,787,856)	(134,354,248)
Total stockholders' equity (deficit)	(1,345,817)	5,718,716
Total Liabilities and Stockholders' Equity (Deficit)	$ 13,496,630	$ 23,700,388

About Reviva Pharmaceuticals Holdings

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentionÃ‚â€“deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.

CEO	Dr. Laxminarayan Bhat Ph.D.
WEBSITE	https://revivapharma.com
INDUSTRY	Biotechnology
EMPLOYEES	10

Reviva Pharmaceuticals Holdings Frequently Asked Questions

What is the ticker symbol for Reviva Pharmaceuticals Holdings? What does RVPH stand for in stocks?

RVPH is the stock ticker symbol of Reviva Pharmaceuticals Holdings. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Reviva Pharmaceuticals Holdings (RVPH)?

As of Fri May 17 2024, market cap of Reviva Pharmaceuticals Holdings is 46.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RVPH stock?

You can check RVPH's fair value in chart for subscribers.

What is the fair value of RVPH stock?

You can check RVPH's fair value in chart for subscribers. The fair value of Reviva Pharmaceuticals Holdings is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Reviva Pharmaceuticals Holdings is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RVPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Reviva Pharmaceuticals Holdings a good stock to buy?

The fair value guage provides a quick view whether RVPH is over valued or under valued. Whether Reviva Pharmaceuticals Holdings is cheap or expensive depends on the assumptions which impact Reviva Pharmaceuticals Holdings's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RVPH.